Physician

Gurpreet Singh Lamba, M.B.B.S.

According to 2025 Medicare claims, Gurpreet Lamba, M.B.B.S. (NPI: 1427294271) practices hematology/oncology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Ocean, NJ. This provider's primary affiliated billing organization is REGIONAL CANCER CARE ASSOCIATES LLC (NPI: 1801850243; TIN: 223141761) and primary practice location at 08753-2974.

Lamba's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,072 traditional Medicare patients, billed 374,824 HCPCS/CPT codes, and received $5,797,276 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,132 prescription claims across 239 beneficiaries totaling $2,594,166 in drug costs, led by Cabometyx (Cabozantinib S-Malate). DME data shows 27 claims. Open Payments data shows 151 records totaling $10,896. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $925,457 to $5,797,276. Similarly, Part D prescription costs have risen steadily, from $338,643 to $2,594,166. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	276	99,358	$925,457
2016	497	165,412	$2,293,947
2017	677	148,235	$2,414,366
2018	652	205,709	$2,325,762
2019	746	224,998	$3,414,741
2020	674	242,044	$4,046,733
2021	763	292,644	$4,043,075
2022	768	311,630	$3,425,322
2023	888	247,267	$3,793,473
2024	1,072	374,824	$5,797,276

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	65	322	$338,643
2016	115	715	$944,201
2017	124	828	$1,003,481
2018	152	981	$1,438,457
2019	161	1,127	$2,087,201
2020	169	1,144	$2,533,415
2021	186	904	$1,902,251
2022	178	864	$1,995,755
2023	209	924	$986,884
2024	239	1,132	$2,594,166

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	22	$3,012
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	12	$226
2024	N/R	27	$759

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	331	1,027	$145
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	409	970	$103
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	365	1,519	$97
36415	Insertion of needle into vein for collection of blood sample	598	2,964	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	488	2,609	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cabometyx	Cabozantinib S-Malate	15	450	$534,979
Calquence	Acalabrutinib Maleate	22	660	$338,605
Jakafi	Ruxolitinib Phosphate	12	360	$194,587
Brukinsa	Zanubrutinib	13	390	$192,046
Eliquis	Apixaban	116	8,016	$152,268

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$477
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$282

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	149	$10,896	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$9,000	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Gurpreet Singh Lamba, M.B.B.S.?

Tedicare shows public-source Medicare data for Gurpreet Singh Lamba, M.B.B.S. (NPI 1427294271), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gurpreet Singh Lamba, M.B.B.S. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Gurpreet Singh Lamba, M.B.B.S.?

Gurpreet Singh Lamba, M.B.B.S. is linked to REGIONAL CANCER CARE ASSOCIATES LLC (billing NPI 1801850243) in the available physician profile data.

Does Gurpreet Singh Lamba, M.B.B.S. have Open Payments data?

Gurpreet Singh Lamba, M.B.B.S. has 151 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.